There are currently 49 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Autism participants are California, Florida, Pennsylvania and New York.
Environmental Exposure and Neurological Diseases Questionnaire
NCT02916966
Recruiting
The proposed research is particularly relevant to the National ALS Registry and public environmental health issues because it addresses the potential environmental causes of sporadic ALS. The research will develop an ALS surveillance program in Ohio that can be compared with the national and State-Metro Surveillance Programs of the National ALS Registry, and novel methodologies to determine the role of the cyanobacterial toxin, BMAA (beta-methylamino-L-alanine), and other environmental toxins/to... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
09/05/2023
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
HEALEY ALS Platform Trial - Master Protocol
NCT04297683
Recruiting
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +76 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
NCT04057898
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/15/2024
Locations: University of California, Orange, California +23 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Neurologic Stem Cell Treatment Study
NCT02795052
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: MD Stem Cells, Westport, Connecticut +2 locations
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Register for Updates
Spinal Cord Associative Plasticity for ALS
NCT06172621
Recruiting
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). As patients await a cure for ALS in the future, patients need more treatments now. The investigators have shown that pairing electrical stimulation over the cervical spinal cord synchronized with magnetic stimulation over the brain can temporarily strengthen weakened nerve circuits between the brain and hand muscles in people with ALS. The current proposal will take the next step of customizi... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/04/2024
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972
Recruiting
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Gender:
All
Ages:
10 years and above
Trial Updated:
04/03/2024
Locations: University of California San Diego, La Jolla, California +19 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
NYSCF Scientific Discovery Biobank
NCT06203106
Recruiting
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.
Gender:
All
Ages:
30 days and above
Trial Updated:
03/21/2024
Locations: New York Stem Cell Foundation Research Institute, New York, New York
Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Register for Updates
Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
NCT02532244
Recruiting
The goal of this study is to establish a genetic registry of patients with early-onset motor neuron and neuromuscular diseases. The investigators will collect samples from patients with a motor neuron or a neuromuscular disorder and their family members. The samples to be collected will be obtained using minimally invasive (whole blood) means. The research team will then extract high quality genomic DNA or RNA from these samples and use it to identify and confirm novel gene mutations and to iden... Read More
Gender:
All
Ages:
1 month and above
Trial Updated:
03/19/2024
Locations: Nemours Children's Hospital Delaware, Wilmington, Delaware +2 locations
Conditions: Spinal Muscular Atrophy, Charcot-Marie-Tooth Disease, Muscular Dystrophy, Spinal Muscular Atrophy With Respiratory Distress 1, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Disease, Peroneal Muscular Atrophy
Register for Updates
Phenotype, Genotype and Biomarkers 2
NCT04875416
Recruiting
The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, the investigator wants to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genoty... Read More
Gender:
All
Ages:
7 years and above
Trial Updated:
03/18/2024
Locations: University of Miami, Miami, Florida +3 locations
Conditions: Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Register for Updates
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
NCT05189106
Recruiting
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers of an ALS-related gene, such as a hexanucleotide expansion in the C9ORF72 gene, with evidence of abnormal inflammatory signaling in cerebrospinal fluid (CSF) at baseline. Each participant will be treated with baricitinib for 24 weeks; no placebo will be given. Participan... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital - ALS Site, Boston, Massachusetts +1 locations
Conditions: Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
Clinical Procedures to Support Research in ALS
NCT03489278
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: University of California, Irvine, Irvine, California +10 locations
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of Alabama Birmingham, Birmingham, Alabama +26 locations
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates